Johnson & Johnson (NYSE:JNJ) Trading 0.7% Higher

Shares of Johnson & Johnson (NYSE:JNJ) rose 0.7% on Monday . The stock traded as high as $165.36 and last traded at $165.36. Approximately 1,317,914 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 7,265,850 shares. The stock had previously closed at $164.13.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Morgan Stanley upped their price target on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $160.00 to $150.00 in a report on Tuesday, July 23rd. TD Cowen dropped their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. The Goldman Sachs Group decreased their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. Finally, Sanford C. Bernstein raised their price target on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $173.21.

Johnson & Johnson Price Performance

The company’s 50 day simple moving average is $153.92 and its 200 day simple moving average is $153.20. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $396.26 billion, a PE ratio of 10.26, a PEG ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. During the same period in the prior year, the firm posted $2.80 earnings per share. The business’s quarterly revenue was up 4.3% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post 10.07 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.01%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JNJ. Tennessee Valley Asset Management Partners grew its position in shares of Johnson & Johnson by 3.1% during the fourth quarter. Tennessee Valley Asset Management Partners now owns 2,666 shares of the company’s stock worth $418,000 after buying an additional 80 shares in the last quarter. GUNN & Co INVESTMENT MANAGEMENT INC. grew its stake in Johnson & Johnson by 1,194.9% during the 4th quarter. GUNN & Co INVESTMENT MANAGEMENT INC. now owns 237,273 shares of the company’s stock worth $37,190,000 after buying an additional 218,949 shares during the last quarter. Duality Advisers LP bought a new position in Johnson & Johnson in the 4th quarter worth about $3,529,000. Telemus Capital LLC increased its position in Johnson & Johnson by 0.5% in the 4th quarter. Telemus Capital LLC now owns 20,157 shares of the company’s stock valued at $3,159,000 after acquiring an additional 104 shares during the period. Finally, Diversified LLC increased its holdings in shares of Johnson & Johnson by 11.8% during the fourth quarter. Diversified LLC now owns 6,469 shares of the company’s stock valued at $1,014,000 after purchasing an additional 682 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.